Table 2.
Induction of PFGs in different HSPC populations. Number of positive reactions combined from four UCB probands is shown (adapted from [94]).
| RUNX1-RUNX1T1 | PML-RARA | KMT2A-MLLT3 | |
|---|---|---|---|
| Po1-C | 0/6 | ND | 0/6 |
| Po1-I | 0/6 | 0/3 | 0/6 |
| Po2-C | 0/9 | 0/6 | 0/9 |
| Po2-I | 0/9 | 0/6 | 0/9 |
| Po3-C | 1/9 | 0/9 | 0/9 |
| Po3-I | 0/9 | 0/9 | 0/9 |
| Po5-C | 0/12 | 0/9 | 0/12 |
| Po5-I | 0/12 | 0/9 | 0/12 |
| Po6-C | 0/9 | 0/12 | 0/12 |
| Po6-I | 0/9 | 0/12 | 0/12 |
| Po7-C | 0/12 | 0/12 | 0/12 |
| Po7-I | 0/12 | 0/12 | 0/12 |
| Po8-C | 0/9 | 0/12 | 0/9 |
| Po8-I | 3/12 | 0/12 | 0/12 |
Abbreviations: ND, not determined; C, control population; I, irradiated population; Po1, B-lymphocytes (Lin− CD45+ CD34− CD19+); Po2, nuclear non-specify lineage negative cells (CD45+ Lin− CD34− CD19−); Po3, HSPCs (Lin− CD45+ CD34+ CD19−); Po4, Pre-Pro B cells (Lin− CD45+ CD34+CD19+); Po5, progenitors (Lin− CD45+ CD45RA- CD34+ CD38+); Po6, HSCs/MPPs (Lin− CD45+ CD45RA− CD34+ CD38−); Po7, HSCs (Lin− CD45+ CD45RA- CD34+ CD38− CD90+); Po8, MPPs (Lin− CD45+ CD45RA- CD34+ CD38− CD90−).